Zhengbin (Bing) Yao currently serves as the CEO and Chairman of the Board at ArriVent Biopharma, specializing in biotechnology and pharmaceutical research, including drug development and early clinical processes. Previously, they held significant leadership roles at companies such as MedImmune and AstraZeneca, where they advanced work in respiratory, inflammation, and immuno-oncology. Bing Yao has also contributed to various boards, including those of Immune-Onc Therapeutics and NiKang Therapeutics. Their academic foundation includes a Ph.D. in Microbiology and Immunology from the University of Iowa.
This person is not in the org chart
This person is not in any teams
This person is not in any offices